Risankizumab is a fully humanized IgG1 monoclonal antibody that selectively targets interleukin-23 (IL-23), specifically its p19 subunit, making it a key biomarker and therapeutic agent in immune-mediated inflammatory diseases. By inhibiting IL-23 signaling, risankizumab effectively downregulates pro-inflammatory pathways involved in the pathogenesis of psoriasis, psoriatic arthritis, and Crohn’s disease. Its mechanism offers a precision approach to immunomodulation, supporting its relevance in both clinical and translational research settings.
Clinically, risankizumab is approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also indicated for active psoriatic arthritis and moderately to severely active Crohn’s disease. Given the chronic and relapsing nature of these conditions, risankizumab’s targeted mechanism allows for long-term disease control, improving patient quality of life and reducing systemic inflammation. The antibody’s effectiveness in multiple autoimmune conditions highlights IL-23 as a central biomarker for therapeutic intervention.
In research and clinical practice, risankizumab serves as a model for biologic development focused on cytokine inhibition. It underscores the importance of therapeutic drug monitoring (TDM) in biologic therapies, especially for managing variability in drug response, immunogenicity, and patient adherence. Its role in advancing personalized medicine is further amplified by the development of biosimilars and ongoing studies exploring its long-term safety, efficacy, and broader applications in immune-related diseases.
This product is manufactured in Turkey by Matriks Biotek.